<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 110 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page109.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=110">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 110 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 110</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=110"><img src="../thumb/110.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Musculo-Skeletal Agents - 4.6                                                   2020-04 / 79
       ulcerat., aphth.stomatit., skin rash, incr. bruis. tendency, alopec., dry   Indications: Act.rheumat.arthrit.in adults as a dis. -modif.antirheu-  discont.if ALT (SGPT) elev.of &gt;3 fold the upper limit of norm. persist.,
       skin, arthralg., extremity pain, amenorrh., fatig., asthen., flu-like illn.,   mat.drug (DMARD)  monit.BP bef.init.treatm.& periodic. thereaft., perform complete bld.
                                                                                     st
       incr.weight, ser.infects.& malign.with high incid.in elderly, COPD exac-  (S4) TABS, 46/3.1/0236, 0237  cell count bef.init. treatm. & thereaft.mnthly x1  6 mnths & then every
       erbat.& dyspn., advers. reacts.more freq.in COPD pts., inj.site reacts.  3000528-001: 10 mg, 30, R769,34  6-8 wks., use with antimalar.in rhemat.dis./ intramusc./ oral gold/D-
       with SC admin., antibody developm., abnorm.LFT.  3000529-001: 20 mg, 30, R782,46  penicillam./azathiopr./ TNF-alpha inhibit.& other immunosuppress.
       Warnings and special precautions: MTX/other non-biolog.  Dosage: Treatm.init.by phys.exper.in rheumatoid arthrit. ALT/CBC   agents not studied, unknown treatm.risk partic.in long term treatm.
       DMARD’s/corticoster./salicylate./ NSAID’s or analges.may be used   incl.WBC & platel.bef.init.ther.& 2 wkly dur 1  6 mnths & 8 wkly.  with combin.ther., combinat.with another DMARD not advis.poss.
                                                        st
       concom., more infect. exper.with concom.TNF block.agents theref.   thereaft. Swall. whole with suff. liq.  lead.to addit./ synergist. tox., poss.incr.S/E with recent hepatotox./
       not recomm., monit.for infect.when transition.from TNF block.ther.,   Init: Load.dos: 100 mg once dly.x3 days. May be init.by 10-20 mg de-  haematotox./immunosuppress.drug treatm., avoid alcohol due to
       vaccinat.respons.& host defenc. against infects.& malign.poss.affect.,   pend.on dis.activ. Recomm. maint: 10-20 mg once dly. Therap.eff.  potent.addit. hepatotox. effs., incr.risk of haematolog.disords.in pts.
       underly. dis.predispos.pts.to infect./hist. of recurr.infects./ chron., la-  usual aft.4-6 wks.with poss.improvem.up to 4-6 mnths. Not recomm.   with pre-exist.bld.dyscras./imp.bone marr. funct./ pts.at risk of bone
       tent or localis. infects., monit.pts.on ther.for new infect.esp.miliary   for use in pts. und.18 yrs.  marrow suppress., perform freq.haematolog.monit.in pts.at risk of
       TB, discont.ther.if ser.infect./sepsis develops, no data avail.on sec-  Contraindications: Hypersens.esp.prev.Stev.-Johns. syndr./tox.  haematologic. disords., discont.in case of sev. haematolog. reacts.
       ond.infect.transmiss.from pts.receiv.live vac.or effs.of vaccinat.in pts.  epiderm.necrolys./erythema multiforme, imp.liv.funct., sev.hypopro-  incl.pancytopen., discont.in case of ulcerat.stomatit./sev.skin or mu-
       receiv.Orencia, concom.live vacc.or within 3 mnths of discont., ren./  teinaem./ immunodefic. states, signif.imp.bone marr.funct./ anaem./   cos. reacts./ sev.uncontrol.infects., incr.suscept.to infects. due to
       hepat. impairm., TB infect.screen., safety with latent TB unknown,   leukopen./neutropen./thrombocytopen. from caus.other than rheu-  poss.immunosuppress., meds.other than NSAID’s metabol.by CY-
       eval.pts.for act.or lat.TB bef.treatm., admin. prophylact.latent TB ther.  mat./psoriat.arthrit., ser. infects., mod.-sev.ren.insuff., pregn.& lactat.,   P2C9, concom. rifampicin, concom.live vaccin.not recomm., early &
       bef.init.ther.& consid. risk vs.benef., screen.pts.for viral hepatit. prior.  excl. pregn. bef.init.ther., women of childbear.potent.to use effect.con-  aggress.treatm.of suspect.infects., liv.funct. impairm., pts to report
       to treatm, anti-rheumat.ther.assoc.with hepatit. B reactivat., potent.  tracept.dur.ther./up to 2 yrs.theraft. as long as plasma lev.of act.me-  pulm.sympts.e.g. cough & dyspn. which should be investigat.to excl.
       role of long term use in malign.develop.unknown, safety & effic.of SC   tabol.above 0,02mg/L, lactat., safety & effic.in pts.und.18 yrs. not est.  interstit. lung dis., monit.tuberculin react.pts.for tuberculos. reactivat.
       admin.in childr.bel. 18 yrs.not est., SC inj.not stud. in juven. idiopath.  Side effects: Freq: Bld.disords., allerg./skin reacts., incr.CPK, CNS   risk, ren.impairm., consid.discont.with periph. neuropathy, INR monit.
       arthrit., sucrose contents for diab. pts., lact intol., if dizz.& reduc.vis.  eff., headache, dizzin., incr.BP, GI disturbs., oral mucos.disords., ten-  with co-admin. warfar.
       acuity exper.avoid driv./operat.machin. hypersens.reacts. incl.ana-  osynovit., anorex., weight/ incr. hair loss, asthen., liv.paramet.elev.   Drug interactions: Incr.prothromb.time with warfarin., cholesty-
       phylax.exper.with IV admin.poss.  Less freq: Sev.infects. incl.fatal seps., infect.susceptibil./malign.risk   ramine & act.charcoal decr. plasma prim.metabol.conc.
       Interactions: Incr.ser.infect.risk exper.with concom. TNF block., ef-  poss. incr., sev.anaphylact./anaphylactoid reacts., vasculit., hypoka-  See also MDR page 102.
       fectiven.of some immunisat. poss. blunted, effs.with agents deplet.  laem., hyperlipidaem., hypophosphataem., incr LDL, anx., periph.
       lymphocyte count not stud.but potent.poss., not recomm.with other   neuropathy, sev.incr.BP, poss.fatal interstit.lung dis., pancreatit., taste   SALAZOPYRIN EN TABS, Pfizer [P/S]
       biolog. rheumat.arthrit.ther.eg.anakinra.  disturbs., hepatit., jaund./ cholestas., sev.liv.inj., tox.epiderm.necrolys.,   Sulphasalazine.
       See also MDR page 285.        Stev. Johns.syndr., erythema multiforme, tend.rupt. Freq. unknown:   Indications: Rheumat.arthrit.
                                                                  (S4) EN TABS. E/20.2.1/910.
       ORENCIA 250 mg, Equity &      Hypouricaem., ren.fail., male fertil. disords.  762016-019: 500 mg, 100, R395,20
                                     Warnings and special precautions: Cons. benef. vs ser.risk
       Abatacept                     fact.with concom.hepatotox./ haematotox. DMARDs bef.init.ther.,   Dosage: Indiv.accord.to respon.& tol.
       Indications: Alone/in combinat.with dis.modify. anti-rheumat.  incr ser. adverse effs.risk for long time aft.when switch.to anoth.   Rheumat.arthrit: Init. 1 tab.in even., grad.incr.to 2 tabs 2xdly by 4th
       meds.(DMARDs) other than tumor necros.fact.block.agents(TNF) to   DMARD without a washout per., ALT/CBC to be check.bef.init.ther.   wk.of treatm. If no respon.aft.2 mnths.dos.may be incr.to 3 g/day.
       reduc.S&S, induc. major clinic.respon, inhib.struct.damage progress.   & 2x mnthly.interv.dur.1  6 mnths.& 8 wkly thereaft., discont.if ALT   Contraindications: Gastr./duoden.ulc., sulphon./ salicyl. hypersens.,
                                               st
       & improv.phys.funct. in adults with act.RA, Reduc. S&S in paed.pts.   elev.of &gt;3-fold the ULN. persist.& init.washout proced., liv. enzym.  porphyr., haemorrhag.diathes., sev.ren./hepat.fail., pregn.& lactat.,
       ≥ 6 yrs.with mod.to sev. act. polyarticul.juven.idiopath.arthrit. & may   monit.maint.aft.ther.discont.unt.lev. norm., BP monit.bef.init.ther.&   infts.& childr. und.2 yrs., childr.with syst.-onset juven.rheum. arthrit.
       be used as adjunct ther.with oth.antirheumat.agents.       Side effects: Headache, fev., GI disturbs., loss of appetite, bld. dys-
       (S4) LYOPHIL.FOR SOL.FOR INFUS., 41/3.1/1061, 250 mg.  per.theraft., avoid alcoh. dur.ther., lact.intol., use with antimalar./IM or   cras., exanthema, urticar., erythema, prurit., orange-yell. col. urine,
                                     oral gold/ D-penicillam./azathioprine/other immunosuppress.agents
       715401-001: sngl.dos.vial.& syr., R2 364,35                CNS eff., periorbit.oed., yellow stain.of soft contact lens., optic neu-
       Dosage: Do not admin.concom.TNF block.agents or other biologic   in rheumat.dis.not stud., monit. recomm.in init.phase aft.switch., com-  ropathy, trans.myop., tinnit., pancreatit., pseudom.colit., ulcerat.co-
                                     bin. with anoth.DMARD not advis.as poss.lead.to addit./ synergist.
       rheumatoid arthrit.ther.eg anakinra. Do not use with siliconis.syringes.   toxic., discont.ther.& init. compl. washout proced.in case of ulc.sto-  lit. exacerbat., hepatit., arthralg., fibros.alveolit., dyspn., cough, skin
       Do not infus in same IV line as other agents. Not stud.in hepat./ren.  matit./ser.skin / mucos. reacts./ sev. haemotolog.eff.incl. pancytopen.,   reacts., photosens., yell.skin discol., alopec., periph. -neuropathy/
       impairm.theref.no dos.recomm.  pre-exist.bld.dyscras./pts.with imp. bone marr. funct./suppress./PML   neurit., asept.meningit., convuls., MS, chorea, depress., exfoliat.
       Concom.methotrex./other non-biolog.DMARDs/ corticosters/salicy-  risk., sev. haemotolog. reacts., no re-challenge aft.sev.skin reacts.,   dermatit., tox.epiderm. necrolys., nephrotox.reacts., Stev. Johnson
       lates/NSAIDs or analges.may be used dur.treatm.  incr.infects.suscept.due to poss. immunosuppress., ther.interrupt./  syndr.due to crystalluria), prot.& haematur., SLE, erythema nodos.,
       Adult rheumat.atrhrit.: Admin.as 30 min.IV infus. &lt;60 kg: 500 mg.   hypothyroid., stomatit., parotit., hypoglycaem.eff. with high dos.,
       60-100 kg: 750 mg. &gt;100 kg: 1 g. Follow.init.infus. admin.at 2 & 4   washout proced. init. if sev.uncontr.infects. occur, monit.pts.with tu-  gen.hypersens./hepatotox.react., anaphylax., oligosperm. & infertil.
                                     berculin reactiv.due to TB reactivat.risk, male-mediat. foet.toxic.risk,
       wks.& then every 4 wks.thereaft. May be used as monother./ con-  (revers.), vertigo, interstit. lung dis., CV effs., leucopen.follow.bone
       com. with DMARDs other than TNF antagon.  monit.pulm.sympts. e.g. cough/ dyspn.& investigat.to excl.ac.interstit.  marr. depress.and red cell abnormalit.
                                     lung dis., concom.meds.metabol.by CYP2C9 other than NSAIDs eg.
       Paed.juven.idiopath.arthrit.: Admin.as 30 min.IV infus. 6-17 yrs.&lt;   Warnngs and special precautions: Adeq.fluid intake, discont.
       75 kg: 10 mg/kg calculat.on pt’s BW at each admin. Paed.pts ≥ 75   phenytoin/warfar./phenprocoumon/ tolbutamide, delay in onset of   if rash appears, gastr.& duod.ulc., period.bld. counts & urine an-
                                     mens./any other reas.to suspect. pregn., instit.washout as describ.
       kg: Admin. follow.adult dos.regim. not exceed.max.dos.of 1000 mg.   in prod.lit.for women wish.to become pregn., pass. into breast milk.  alys, G6PD defic., great. incid.of adverse eff.in AIDS pts., pts.with
       Follow.init.infus. admin.at 2 & 4 wks.& then every 4 wks.thereaft.  slow acetylat. phenotype are more likely to show adverse eff., ren.
       Contraindications: Act./dorm.untreat.TB., pregn. & lactat., hyper-  Interactions: Incr.S/E poss.with concom./recent hepatotox./ haemo-  impairm., poss.serum-like react.in childr. with system.-onset rheum.
                                     totox.meds.or when treatm.foll. by such meds.with.washout per., liv.
       sens./any compon.hypersens.                                arthrit., folic acid defic.poss. result.in ser.haematolog.toxic./ terato-
       Side effects: Hypersens.reacts.incl.anaphylax., headache, naus.,   enzym.elev. with methotrex., cholestyramine & act.charcoal decr.   genic., sev.allerg/bronch.asthma, pass.into breastmilk, prem/G6PD
                                     plasma prim.metabol.conc., prim.metabol. peak lev.incr.with rifampic-
       U&LRTI, UTI, H.simplex, rhinit., tooth infect., infect.skin ulc., onycho-  infts.if breastfed, bld. dyscras.
       mycos., basal cell Ca, bld.dyscras., depress., anx., dizzin., paraes-  in, vaccinat.with live attenuat.vaccin.not recomm.  Drug interactions: Bld.sugar reduc.eff of sulphonylureas enhanc.,
       thes., conjunctivit., reduc.vis.acuity, vertigo, tachycard., bradycard.,   RHEUMALEF, Adcock Ingram [P/S] &  poss.interacts.with coumarins, methotrex., probenecid, rifampic.,
       palpitat., hyper-/hypotens., flush., cough, abdom.pain, diarrh., pyrex.,   Leflunomide  sulfinpyrazone, spironolact., furosemide & potent. of undesir.glu-
       dyspeps., gastrit., mouth ulcerat., aphth.stomatit., skin rash, incr.bruis.  Indications: Act.rheumat.arthrit.in adults as a dis. modify.antirheu-  cocortic.eff.on stomach, Fe chelat.& absorpt. interfer.with, PABA &
       tendency, alopec., dry skin, arthralg., extremity pain, amenorrh., fatig.,   mat.drug (DMARD).& to improv. physic. funct.  deriv.compnds.may antagon.act., acetylat incr.by paraldehyde, reduc.
       asthen., flu-like illn., incr.weight, ser.infects., malign., COPD exacer-  (S4) TABS, 45/3.1/0404, 0405  folate & digox.absorpt., alter.pt.respons.with concom. antibiot., eff.of
       bat. & dyspn., antibody developm., advers. reacts.more freq.in COPD   721609-001: 10 mg, 30, R775,35  oral coagul., methotrex.& phenytoin potent., incr.crystallur risk with
       pts., caut.in elderly as high.infect.& malign.incid.report., abnorm.LFT  721610-001: 20 mg, 30, R791,32  compnds. that acidify urine, folic acid absorpt./ metabol. inhib.poss.
       Warnings and special precautions: More infect. exper.with con-  Dosage: Treatm.only by drs exper.in rheumatoid dis.  caus.folic acid defic., bone marr. suppress./leukopen.with concom.
       com.TNF block.agents theref. not recomm., monit.for infect.when   Init.dos: 100 mg once dly.x3 days. Recomm. maint: 10-20 mg once   thiopurine 6-mercaptopurine /azathioprine
       transition.from TNF block.ther., vaccinat.respons. & host defenc.   dly. Therap.eff. usual aft.4-6 wks.with poss.improvem.up to 4-6 mnths.
       against infects.& malign.poss.affect., underly.dis. predispos.pts.to   Contraindications: Imp.liv.funct., sev. immunodefic. states, signific.  SIMPONI, Janssen Pharmaceutica (Pty) Ltd.
       infect./hist.of recurr.infects./ chron., latent or localis.infects., monit.  imp.bone marr.funct. /signif.anaem., leukopen/neutropen/ thrombo-  See Section 24.1
       pts.on ther. develop.new infect., discont.ther.if ser.infect./ sepsis de-  cytopen. from causes other than rhemat. arthrit., ser.infects., mod.-  SUPLASYN, Pharmaco
       velops, no data avail.on second.infect. transmiss.from pts.receiv.live   sev.ren.insuffic., sev. hypoproteinaem., pregn., women of childbear.
       vac.or effs.of vaccinat.in pts.receiv.Orencia, do not admin. concom.  potent (unless adeq.contracept.), lactat., pts.und. 18 yrs.as safety &   Purif.hyaluron.acid sod.salt (Sodium hyaluronate)
                                                                  Indications: Tempor.replacem.of synovial fluid follow.arthrocentes.
       live vacc.or within 3 mnths of discont., ren./ hepat.impairm., monit.  effic.not studied, concom. DMARD not recomm., concom.cholesty-
       for infects.incl.miliary TB dur./aft.treatm., safety with latent TB un-  ramine., lact.intol.  in non-infect.knee joints not prev.treat.with either intra-articulate hya-
                                                                  luron. acid or glucocortis.inj.
       known, eval.pts.for act.or lat.TB bef.treatm., admin. prophylact. la-  Side effects: GI disturbs., liv.paramet.elev., hepatit., jaund., choles-
       tent TB ther.bef.init.ther.& consid.risk vs.benef., screen.pts.for viral   tas., pancreatit., sev.liv. injur., hepat.fail., ac.hepat.necros., incr.BP, bld.   (S4) INJ, A39/3.2/0352. 10 mg/ml
                                                                  713683-001: 20 mg/2 ml, 1 pre-fill.syr., R550,60
       hepatit.prior.to treatm, hepatit.B reactivat.assoc.with anti-rheumat.   dyscras., CNS effs., periph neuropathy, allerg./ anaphylact.reacts/skin   721958-001: 60 mg/6 ml, 1 pre-fill.syr., R1 775,72
       ther., potent.role of long term use in malign. develop.unknown, pts.  reacts.incl.Stev.Johns. syndr./ erythema multiforme & tox.epiderm.
       with juven.idiopath. arthrit. should be up to date with all immunisat.  necrolys., hair loss, pustul./worsen.psorias., vasculit., sev.infects.  Dosage: Admin.by train.healthcare prof.only. Bring to room temp.
                                                                  bef.inj.
       in agreem. with curr.immunisat.guidelines prior to init.ther., not advis.  incl.sepsis, interstit.lung dis., weight loss, anorex., asthen., incr.CPK,
       in pts.und.6 yrs.as safety & effic. not est., safety & effic.in paed.pts.  hypokalaem., mild hyperlipidaem., hyperphosphat., incr. LDH, decr.  Up to 2 ml intra-articularly depend.on joint size. Recomm.sched: 1
                                                                  inj./wk x3 wks. May be rep.in 6 mnths. Safety & effic.of 2 consecut.
       for uses other than juven.idiopath.arthrit.not est., if bld. gluc.monit.  uric acid levs., incr malign.risk partic. lymphoproliferat.disords.with
       reqd.consid.tests not react.with maltose, if dizzin./reduc.vis.acuity   some immunosuppress. drugs, progress. multifoc. leukoencepha-  courses not est.
                                                                  Contraindications: Known hypersens.reacts., safety in pregn.&
       exper.avoid driv./operat.mach.  lopathy, ren.fail., tenosynovit., tend. rupt., decr.sperm conc./count
       Drug interactions: Incr.ser.infect.risk exper.with concom.TNF block.,   & rapid progress. motility.  lactat.not est.
       effectiven.of some immunisat. poss.blunted, effs.with agents deplet.  Warnings and special precautions: Teratogen. in rats & rabbits,   Side effects: Trans.short durat.loc.pain, loc. feel. of heat/
       lymphocyte count not stud.but potent.poss., not recomm.with other   male pts.to be aware of poss. male-mediat.foet.toxic., without drug   redn.&swell., strong. loc.reacts.as sign of hypersens./anaphy-
       biolog.rheumat.arthrit.ther.eg anakinra as safety & effic.not est.  elimin. proced. it may take up to 2 yrs.to reach prim. metabol. lev.  lax.& fev.
       See also MDR page 287.        of &lt;0,02 mg/L, instit.washout as describ. in lit.for any women wish.  SYNVISC, (Sanofi) Genzyme
       PLASMOQUINE, Medchem Pharmaceuticals (Pty) Ltd  to fall pregn./ men wish.to father childr./when switch.to another   Hylan (G-F 20)
       See Section 18.11             DMARD aft. treatm./if sev.haematolog./sev.skin reacts./ sev.uncon-  Indications: Pain treatm.in osteoarthros.of knee fail.to respond adeq.
                                     trol.infects.occur, contracept. other than OC’s recomm.dur.washout,   to conservat.non-pharmacolog. ther.& analges.
       RAVALEF, Activo [P/S]         reliab. contracept., for use by exper.physic.only, check ALT(SGPT) bef.  (S4) INJ, 45/3.2/0025. 8 mg/ml
       Leflunomide                   init.ther.& at mnthly interv.x 1  6 mnths. & every 6-8 wks.thereaft.,   720405-001: 1x sngl.use prefill.syr., R2 615,79
                                                 st</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page109.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page105.html">105</a>&nbsp;&nbsp;&nbsp;<a href="page106.html">106</a>&nbsp;&nbsp;&nbsp;<a href="page107.html">107</a>&nbsp;&nbsp;&nbsp;<a href="page108.html">108</a>&nbsp;&nbsp;&nbsp;<a href="page109.html">109</a>&nbsp;&nbsp;&nbsp;<a href="page110.html">110</a>&nbsp;&nbsp;&nbsp;<a href="page111.html">111</a>&nbsp;&nbsp;&nbsp;<a href="page112.html">112</a>&nbsp;&nbsp;&nbsp;<a href="page113.html">113</a>&nbsp;&nbsp;&nbsp;<a href="page114.html">114</a>&nbsp;&nbsp;&nbsp;<a href="page115.html">115</a>
             </td>
             <td width="35%"><a href="page111.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page111.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
